{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-004055","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.963364+00:00","generated_at":"2026-05-16T07:16:44.743615+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Enveric Biosciences raises ~$1.5M in registered direct offering with warrants","bullets":["Sold 328,802 shares at $4.41 per share in a registered direct offering, gross proceeds ~$1.5M.","Concurrent private placement: Series G and H warrants to buy up to 328,802 shares each at $4.16.","Series G warrants expire 5 years after resale registration effective date; Series H expire 18 months after.","Net proceeds ~$1.25M for product development, working capital, general corporate purposes.","H.C. Wainwright acted as placement agent; fees include 7% cash and placement agent warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-004055","json":"https://secwatch.observer/filing/0001493152-26-004055.json","markdown":"https://secwatch.observer/filing/0001493152-26-004055.md","text":"https://secwatch.observer/filing/0001493152-26-004055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315226004055/0001493152-26-004055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315226004055/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:16:44.743615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb6f908d12ec2e6c4162ec6d66b17f3e5df4097b","claim":"Enveric Biosciences, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $1.5 million (effective 2026-01-27).","evidence_excerpt":"On January 27, 2026, Enveric Biosciences, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (each, an “Investor”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315226004055/0001493152-26-004055-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $1.5 million"},{"label":"Effective","value":"2026-01-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}